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Abstract: The non-steroidal anti-inﬂ  ammatory drug (NSAID) ketorolac tromethamine 0.4% 
ophthalmic solution, a recent reformulation containing 20% less active ingredient that the original 
formulation, is indicated for the reduction of ocular pain and burning/stinging following corneal 
refractive surgery. Clinical studies have shown ketorolac tromethamine 0.4% to be as effective 
as ketorolac tromethamine 0.5% to control inﬂ  ammation after cataract surgery including pre-
vention of cystoid macular edema (CME). Its efﬁ  cacy to inhibit miosis during cataract surgery 
as well as its role in the treatment of dry eye has been reported. The purpose of this paper is to 
review the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inﬂ  ammation 
following cataract and refractive surgery.
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Nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) inhibit production of prostaglandins 
(PG) by inhibiting cyclo-oxygenase (COX) which is the main enzyme to produce 
eicosanoids (ie PG and thromboxanes). Two isoforms of COX (COX-1 and COX-2) 
with different physiological properties have been described (Warner and Mitchell 
2004). COX-1 seems to be responsible for the physiological production of prostanoids 
while COX-2 is associated to the pathological function and inﬂ  ammation. COX-1 
and COX-2 are very similar in its aminoacid composition as well as molecular mass, 
intracellular location and function. However, there are differences such as different gene 
location, COX-1 is located in chromosome 9 while COX-2 is situated in chromosome 
1. Furthermore, the amino acid at positions 434 and 523 in COX-1 is isoleucine and in 
COX-2 is valine (Warner and Mitchell 2006). Systemically, COX-1 has been associated 
with gastrointestinal side effects whereas COX-2 produces less gastrointestinal adverse 
events (Warner and Mitchell 2004, 2006). However, COX-2 selective inhibitors have 
been shown to increase the risk of serious cardiovascular adverse events, primarily 
acute myocardial infarction (Furberg 2006).
The effect of COX-2 as a therapeutic target in inﬂ  ammation, pain, cancer, and its 
effect on the central nervous system (CNS), kidney, reproductive, gastrointestinal, 
and respiratory tracts as well as in the pancreas and cardiovascular system have been 
reported (Warner and Mitchell 2004). A third COX isoform has been described (COX-3); 
however, this form does not have the COX activity, and therefore, it is unlikely to have 
an impact in the PG production (Warner and Mitchell 2004, 2006; Hersh et al 2005).
The eye, after chemical, mechanical and thermal stimuli, has a wide range of 
inﬂ  ammatory responses, many of which involve PG formation from arachidonic acid. Clinical Ophthalmology 2007:1(4) 368
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The PG and leukotriene synthesis after surgical trauma has 
been described in detail in previous publications (Flach 1992; 
Nichols and Snyder 1998; Perry and Donnenfeld 2006). The 
PG formation leads to the blood aqueous barrier breakdown, 
decreases the pain threshold and increases photophobia. Other 
ocular inﬂ  ammation signs include hyperemia, miosis, and 
decreased vision. The control of inﬂ  ammation within the eye 
is mandatory to keep the ocular integrity and function. The 
inﬂ  ammatory cascade can be blocked at different locations 
using different therapeutic agents (ie, the release of arachidonic 
acid can be impeded by blocking the phospholipase A2 
activity using corticosteroids, NSAIDs can interfere with the 
COX-1 and COX-2 activity). It has been shown that NSAIDs 
also suppress polymorphonuclear cell ability to move and 
chemotaxis; decrease expression of inﬂ  ammatory cytokines 
and mast cell degranulation (Gaynes and Fiscella 2002).
In ophthalmology, NSAIDs are commonly used to 
prevent intraoperative miosis during cataract surgery, to 
reduce postoperative inﬂ  ammation and to prevent cystoid 
macular edema (CME) following cataract extraction, relief 
of seasonal allergic conjunctivitis symptoms, reduction of 
ocular discomfort (pain and photophobia) after refractive 
surgery, and to treat CME once it occurs.
The purpose of this paper is to review the use of ketorolac 
tromethamine 0.4% in the treatment of post-surgical inﬂ  am-
mation following cataract and refractive surgery.
Characteristics
Ketorolac tromethamine 0.4% (Acular® LS, Allergan, Inc, 
Irvine, CA, USA) was introduced in the United States 
in 2003. It is a member of the pyrrolo-pyrrole group of 
NSAIDs used in ophthalmology. Its chemical name is 
(±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, 
compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol 
(1:1). It is a racemic mixture of R-(+) and S-(−)- ketorolac 
tromethamine, which exists in three crystal forms which are 
equally soluble in water. Other characteristics include a pH 
of 7.4 and an osmolality of 290 mOsml/kg, pKa is 3.5 and its 
molecular weight is 376.41. Ketorolac tromethamine 0.4% 
and ketorolac tromethamine 0.5%, the original formulation, 
(Acular, Allergan, Inc, Irvine, CA, USA), share the men-
tioned characteristics. Acular 0.4% contains 20% less active 
ingredient than the original formulation. Other differences 
among the 2 solutions include the preservative concentra-
tion, ketorolac 0.5% contains 0.01% benzalkonium chloride 
while ketorolac 0.4% contains 0.006%. The concentration of 
edetate disodium, an inactive ingredient, is 0.1% and 0.015% 
in ketorolac 0.5% and 0.4%, respectively.
Mechanism of action
Systemically, ketorolac tromethamine has shown anti-
inﬂ  ammatory, analgesic and antipyretic action (Litvak and 
McEvoy 1990). Many of these activities appear to be associated 
mainly with the inhibition of PG biosynthesis by inhibiting 
the COX enzymatic system (Litvak and McEvoy 1990; Jay 
1991). The effect of ketorolac ophthalmic solution is thought 
to be due to the inhibition of ocular PG synthesis (Litvak and 
McEvoy 1990).
Waterbury and Flach (Waterbury and Flach 2006) using 
a rabbit model of ocular inﬂ  ammation induced by injecting 
a lipopolysaccharide endotoxin isolated from Salmonella 
enterica intravenously investigated the anti-inﬂ  ammatory 
activity of ketorolac 0.4% and other NSAIDs. They reported 
a nearly complete inhibition of PG synthesis in the aqueous 
humor compared with vehicle.
In a similar animal model, Waterbury et al (2004) 
evaluating the COX activity and anti-inﬂ  ammatory effect 
of ketorolac 0.4% found that ketorolac 0.4% is a relatively 
COX-1 selective NSAID with potent ocular anti-inﬂ  ammatory 
action producing almost complete inhibition of PG synthesis 
in aqueous humor in the treated eyes. These ﬁ  ndings are 
similar to previous studies conducted in rats (Pallapies et al 
1995; Jett et al 1999) which have shown than ketorolac 
tromethamine is a potent inhibitor of COX-1 and 2.
Pharmacokinetics
In rabbit eyes, ketorolac 0.5% is distributed throughout 
all the ocular tissues (Ling and Combs 1987; Litvak and 
McEvoy 1990). After topical application of ketorolac 0.5%, 
peak plasma levels of approximately 0.2 μg/mL within 15 
minutes after application were detected (Ling and Combs 
1987). In the US Food and Drug Administration (FDA), 
safety sheet data, it is reported that 5 out of 26 normal 
patients, after application of one drop of ketorolac 0.5% 
3 time a day for 10 days, showed ketorolac plasma levels 
between 10.7 and 22.5 ng/mL at day 10.
Indications
One drop of ketorolac tromethamine 0.5% 4 times a day 
is indicated for the temporary relief of ocular itching due 
to seasonal allergic conjunctivitis, and one drop 4 times a 
day starting 24 hours after the procedure and continuing for 
2 weeks for the treatment of postoperative inﬂ  ammation 
following cataract surgery.
Ketorolac tromethamine 0.4% is indicated for the reduc-
tion of ocular pain and burning/stinging following corneal 
refractive surgery. The recommended dosage is one drop Clinical Ophthalmology 2007:1(4) 369
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4 times a day in the operated eye as needed for up to 4 days 
following corneal refractive surgery.
Adverse effects
Keratitis, corneal subepithelial inﬁ  ltrates, ulceration, and 
corneal melt are adverse events that have been associated 
with the use of NSAIDs (Teal et al 1995; Guidera et al 2001; 
Solomon et al 2001). Transient stinging and burning on instil-
lation of ketorolac tromethamine 0.5% was reported by 40% 
of subjects participating in clinical trials (FDA safety sheet 
data). The reduction in the concentration of ketorolac would 
decrease patient complaints of stinging and burning after its 
instillation (Solomon et al 2004; Sandoval et al 2006).
Clinical studies evaluating ketorolac 
tromethamine 0.4%
Ketorolac tromethamine 0.4% post 
photorefractive keratectomy (PRK)
A few studies have been published in the peer reviewed lit-
erature regarding the use of ketorolac tromethamine 0.4%.
Solomon et al (2004) in a large, two multi-center, ran-
domized, double-masked vehicle controlled study involving 
313 eyes of 313 subjects evaluated the safety and analgesic 
efﬁ  cacy of ketorolac 0.4% after PRK. In this trial, patients 
were treated with one drop of either ketorolac 0.4% (n = 
156) or its vehicle (n = 157), 4 times a day for up to 4 days. 
Measured outcomes included pain intensity, pain relief, use 
of escape medication, and severity of ocular symptoms. The 
results of this study showed that compared with the vehicle 
patients, ketorolac 0.4% was associated with signiﬁ  cantly 
reduced ocular symptoms (burning/stinging, 25.0% vs 
47.8%; foreign body sensation, 36.5% vs 58.9%; photopho-
bia, 49.4% vs 71.3%; and tearing, 49.4% vs 71.3%). During 
the ﬁ  rst 12 hours after surgery, fewer patients in the ketorolac 
0.4% group had severe to intolerable pain (41.6% vs 84.4%) 
and required less escape oral pain medication (45.5% vs 
90.4%). These results were statistically signiﬁ  cant. There 
were no signiﬁ  cant differences among the two groups for 
any reported adverse events.
Ketorolac tromethamine 0.4% 
and cataract surgery
A prospective, double-masked study including 40 eyes of 40 
patients to compare the effectiveness and patient tolerance 
of ketorolac 0.4% (n = 20) compared with ketorolac 0.5% 
(n = 20) after routine phacoemulsiﬁ  cation and lens implanta-
tion was conducted by Sandoval et al (Sandoval et al 2006). 
The assigned treatment was started 15 minutes prior to 
surgery and subjects were instructed to continue using it 4 
times a day after surgery for 1 week and twice a day for the 
following 3 weeks. Assessments included best-corrected 
visual acuity (BCVA), slit-lamp (SL) cell evaluation, intra-
ocular pressure (IOP), laser cell and ﬂ  are measurements, and 
subjective patient tolerance. The authors found that at day 1 
after surgery, 70% of patients in the ketorolac 0.5% group 
reported more symptoms mainly foreign body sensation 
and stinging/burning compared with 40% in the ketorolac 
group. No signiﬁ  cant differences were found in BCVA, SL 
cell evaluation, IOP, and laser cell and ﬂ  are measurements. 
The authors concluded that ketorolac 0.4% has the same 
effectiveness to reduce anterior segment inﬂ  ammation after 
routine cataract surgery than ketorolac 0.5% with less patient 
discomfort.
Price and Price (2004) studied the efﬁ  cacy of ketorolac 
0.4% to control pain and discomfort associated with cataract 
surgery. In this single-center, double-masked, randomized, 
fellow-eye placebo-controlled trial, they included 25 sub-
jects undergoing bilateral cataract extraction. The treatment 
(ketorolac 0.4% or artiﬁ  cial tears) was randomized to the 
ﬁ  rst eye undergoing surgery and the second eye received 
the alternate treatment. Patients were instructed to use the 
assigned treatment four times a day starting 3 days prior to 
and 1 day after surgery. Patient cooperation and ocular pain 
or discomfort during surgery was evaluated by the surgeon 
while patients rated ocular pain and discomfort immedi-
ately and 24 hours postoperatively. The results showed that 
patients in the ketorolac 0.4% reported signiﬁ  cantly less 
ocular pain during the 24 hours after the procedure than the 
control group (4% vs 39%). No signiﬁ  cant differences among 
the groups were detected in patient cooperation, ocular pain 
and discomfort during or immediately after surgery. No 
adverse events occurred during this trial.
An assessment of the clinical beneﬁ  t, relative efﬁ  cacy, 
and pharmacokinetic-response curve of preoperative and 
postoperative ketorolac tromethamine 0.4% to improve 
outcomes during and after cataract surgery was performed 
by Donnenfeld et al (2006). In this prospective, double-
masked study, patients were randomized to 1 of 4 groups of 
25 subjects each. Group 1 received ketorolac 0.4% 4 times 
a day for 3 days and 3 times every 15 minutes in the hour 
before surgery; group 2, ketorolac 0.4% 4 times a day for 1 
day prior to surgery and 3 times every 15 minutes in the hour 
before surgery; group 3, ketorolac 0.4% every 15 minutes 
in the hour before surgery; and group 4, had no predosing 
schedule and received vehicle only every 15 minutes in the Clinical Ophthalmology 2007:1(4) 370
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hour before surgery. Postoperatively, all subjects in the 4 
treatment groups received ketorolac 0.4% for 3 weeks; the 
placebo group received vehicle. Preservation of preoperative 
mydriasis, phacoemulsiﬁ  cation time and energy, operative 
time, corneal clarity, endothelial cell counts, postoperative 
inﬂ  ammation, intraoperative and postoperative discomfort, 
complications, and incidence of clinically signiﬁ  cant CME 
were evaluated. The authors reported that pupil size was 
maintained signiﬁ  cantly better in groups 1 and 2 than in 
groups 3 and 4. The use of ketorolac 0.4% 1 and 3 days 
before surgery decreased surgical time, phacoemulsiﬁ  ca-
tion time and energy, and endothelial cell loss; it improved 
visual acuity outcomes. CME was observed in 4% and 12% 
in groups 3 and 4, respectively while none of the patients is 
groups 1 and 2 presented it.
Ketorolac tromethamine 0.4% 
and dry eye
A clinical study was conducted to determine the role of 
ketorolac 0.4% as adjuvant in the induction phase of chronic 
dry eye treatment when combined with cyclosporine-A. In 
this single-center, randomized, open labeled trial patients 
received either cyclosporine-A combined with artiﬁ  cial tears 
(n = 27) or with ketorolac 0.4% twice a day (n = 25). Corneal 
staining, Schirmer’s test (with anesthesia), tear break-up time 
(TBUT), ocular comfort, and an ocular surface index (OSDI) 
were assessed. The combined treatment with ketorolac pro-
vided signiﬁ  cant greater improvement in ocular comfort at 
2 weeks compared with the control group. Mean reduction in 
corneal staining as well as mean OSDI scores were greater 
in the cyclosporine-A + ketorolac 0.4% group at 2 and 6 
weeks. No differences in mean change in Schirmer’s test 
and TBUT were observed. No corneal adverse events were 
noted (Schechter 2006).
Summary
Ketorolac tromethamine, a NSAID, has been widely use in 
ophthalmogy. In reported clinical trials, it has been shown to 
be highly effective in relieving pain after radial keratotomy 
(RK) (Yee 1998; McDonald et al 1999), photorefractive 
keratectomy (PRK) (Rajpal and Cooperman 1999), laser in 
situ keratomileusis (LASIK) (Kosrirukvongs et al 2001); 
and to treat allergic conjunctivitis (Yaylali et al 2003). Its 
efﬁ  cacy to reduce inﬂ  ammation after cataract surgery has 
been shown (Solomon et al 2001) and it has been compared 
with the efﬁ  cacy of topical steroids after extra-capsular 
cataract extraction (Flach et al 1988; Simone et al 1999) and 
phacoemulsiﬁ  cation (Solomon et al 2001; Holzer et al 2002). 
The effectiveness of ketorolac 0.5% in the treatment of 
aphakic and pseudophakic macular edema has been also 
described (Flach 1987).
The relative new reformulation of ketorolac tromethamine 
0.4% containing 20% less active ingredient indicated for the 
reduction of ocular pain and burning/stinging following cor-
neal refractive surgery has been proven in different studies 
to be as effective as the original formulation to reduce ante-
rior segment inﬂ  ammation as well as to prevent CME after 
routine cataract extraction. Reduction in patient complaints, 
intraoperative maintenance of pupil size, improvement of 
visual outcomes, and it use as adjuvant in the initial treatment 
phase of chronic dry eyes has been also shown.
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